Compugen

Drug Discovery Using Computational Modeling

Health Tech & Life Sciences
Public on NASDAQ on Aug, 2000
Public on TASE on Jan, 2002

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees and has raised a total of $141.92M across seven funding rounds. The company went public on NASDAQ in August 2000 and on TASE in January 2002. In October 2018, Bristol-Myers Squibb Company invested in Compugen.

Business overview

Compugen is a clinical-stage drug discovery and development company specializing in immuno-oncology. The company leverages a predictive-discovery infrastructure to advance a therapeutic pipeline focused on novel immune checkpoint candidates designed to treat various cancer types and patient populations. Compugen's core technology involves computational modeling to identify drug targets, primarily in oncology and immunology, and it has expanded its capabilities to include myeloid target candidates within the tumor microenvironment. Its products, including COM902/TIGIT, COM701/PVRIG, ILDR2/BAPOTULIMAB, and COM503/IL18-BP, are aimed at harnessing the immune system to eradicate cancer, serving the pharmaceutical and healthcare industries, with a focus on patients in Israel, the United States, and Canada.

Strategic signal

Compugen is actively engaged in presenting its clinical and pre-clinical data at major scientific conferences, signaling ongoing research and development momentum. For instance, in October 2025, the company is scheduled to present at SITC 2025, and in September 2025, it will present research at the Single Cell Genomics 2025 Conference. These consistent presentations demonstrate the company's commitment to sharing scientific advancements and validating its computational target discovery platform, which is crucial for attracting partnerships and investment in the highly competitive immuno-oncology space.

Company Intelligence Q&A

What was a significant financial milestone for Compugen in 2000?
Compugen went public on NASDAQ in August 2000, marking a key transition for the company.
When did Compugen expand its intellectual property with a new Japanese patent?
In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.
What clinical data did Compugen present in November 2023?
In November 2023, Compugen presented data indicating that its COM701 (anti-PVRIG) mediates anti-tumor activity in patients who typically do not respond to immunotherapy.
What was a notable investment in Compugen in October 2018?
In October 2018, Bristol-Myers Squibb Company invested $12 million in Compugen for a tumor collaboration, as reported by Globes.
What is Compugen scheduled to present at ESMO in October 2025?
In October 2025, Compugen is scheduled to present a pooled analysis of COM701 in three Phase 1 trials in patients with platinum-resistant ovarian cancer at ESMO 2025.

External links